Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 16/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | RAF1 | P04049 | 2/20 | 0.42 |
| ▸ | YES1 | P07947 | 1/20 | 0.42 |
| ▸ | BMX | P51813 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4631512 | 0.89 | BRAF (0.57) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL4877906 | 0.88 | RAF1 (0.52) | BRAFRAF1 | |
| SCHEMBL4882776 | 0.81 | BRAF (0.57) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL4631343 | 0.80 | BRAF (0.58) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL4878345 | 0.78 | RAF1 (0.53) | BRAFRAF1 | |
| SCHEMBL27708222 | 0.77 | PIKFYVE (0.55) | BRAF | |
| SCHEMBL4877170 | 0.75 | BRAF (0.63) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL4630922 | 0.73 | BRAF (0.59) | MAPK14BRAFCYP2C9RAF1YES1 | |
| SCHEMBL4973741 | 0.72 | BRAF (0.51) | BRAFCYP2C9KDR | |
| SCHEMBL4630979 | 0.71 | BRAF (0.68) | MAPK14BRAFKDRRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146570-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146570-A1 | Chemical Compounds | BRAF, RAF1, NRAS | MAPK14 226/4885BRAF 1/4885CYP2C9 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.